Sartorius has launched the modular Eveo Cell Therapy Platform, an integrated system for the production and quality control (QC) of autologous cell therapies designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments.

“Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on,” said René Fáber, member of the Executive Board at Sartorius. “By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients.”

Conventional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, that require significant greenfield investment, staff recruitment, training and multi-year build-up phases. Nevertheless, the majority of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues.

The new Eveo platform is designed to address these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies. The system’s compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralized and decentralized manufacturing models.

Quality control also represents a major bottleneck in cell therapy production and release. With Sartorius’ capabilities in live cell imaging and high throughput flow cytometry included in the Eveo platform, the technology addresses key analytical challenges and enables accessibility.

Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027.

More Sartorius News

Earlier this year, Sartorius expanded its bio-based product portfolio and launched a new genetically engineered CHO host cell line.